Cambridge, Massachusetts, United States Lysosomal Therapeutics appeared to be the Corporate Investor, which was created in 2014. The venture was found in North America in United States. The main office of represented Corporate Investor is situated in the Cambridge.
The fund has specific favorite in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Aura Biosciences, Artax Biopharma, NanoString Technologies. We can highlight the next thriving fund investment areas, such as Neuroscience, Biotechnology. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year. This Lysosomal Therapeutics works on 4 percentage points less the average amount of lead investments comparing to the other organizations. The higher amount of exits for fund were in 2013. The important activity for fund was in 2015.
The usual cause for the fund is to invest in rounds with 4 partakers. Despite the Lysosomal Therapeutics, startups are often financed by Clarus Ventures, Realiza Business Angels, ALS Finding a Cure. The meaningful sponsors for the fund in investment in the same round are Advent Life Sciences, Ysios Capital, OVP Venture Partners. In the next rounds fund is usually obtained by DFJ, Clarus Ventures, Ysios Capital.
The current fund was established by Dimitri Krainc, Edmund Sybertz, Henri Termeer, Joseph Mazzulli, Kees Been, Peter Wirth.
Related Funds
| Fund Name | Location |
| Albion Investors | New York, New York, United States |
| Beijing Jiangyuan Yade Touzi | Beijing, Beijing, China |
| CANDEAL | Japan, Tokyo |
| CXT Investments | - |
| DHS | - |
| Encore Capital | England, London, United Kingdom |
| Experian Ventures | California, San Francisco, United States |
| Fusheng Touzi | China, Hangzhou, Zhejiang |
| Huangting Capital Management | China, Guangdong, Shenzhen |
| KGC Capital | Chicago, Illinois, United States |
| Kraft Heinz | Mendota, Minnesota, United States |
| MAKOTO | Japan, Miyagi Prefecture, Sendai |
| Phoenix Insurance Company | Israel, South Dakota, United States |
| Resolution Capital Limited | Australia, New South Wales, Sydney |
| Sekisui Chemical Company | Japan, Osaka, Osaka Prefecture |
| Turim MFO | Brazil, São Paulo, Sao Paulo |
| XL Innovate | California, Menlo Park, United States |
| Yindinghui Zichan | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Amylyx Pharmaceuticals | $5M | 22 Aug 2016 | Cambridge, Massachusetts, United States | ||
Artax Biopharma | $10M | 22 Sep 2015 | Cambridge, Massachusetts, United States | ||
Aura Biosciences | $21M | 05 Mar 2015 | Cambridge, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Amylyx Pharmaceuticals | $5M | 22 Aug 2016 | Cambridge, Massachusetts, United States | ||
Artax Biopharma | $10M | 22 Sep 2015 | Cambridge, Massachusetts, United States | ||
Aura Biosciences | $21M | 05 Mar 2015 | Cambridge, Massachusetts, United States |
